Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Scribe Therapeutics

Main focus: Development of CasX for therapeutic use in genetic diseases

Company stage: Pre-clinical

Diseases: Amyotrophic lateral sclerosis (ALS), otherwise undisclosed

Genome editing tool: CRISPR-CasX

Funding stage: Private

Location: San Francisco Bay Area, California, United States

Website: https://www.scribetx.com/

Partners: Biogen

Scribe Therapeutics develops novel Cas variants, in particular the CasX enzyme, for the treatment of genetic diseases. The company has yet to disclose its pre-clinical pipeline. However, it has unveiled a collaboration with Biogen focusing on ALS.

Tags

HashtagScribe Therapeutics

Company: Scribe Therapeutics
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine